Ten years ago, the pharmaceutical firms focused on primary care indications, and subsequently the odds of getting these primary care drugs to the market are a little bit lower.
Investors should keep a close watch on the switch from Celexa to Lexapro and not worry too much about new indications for memantine, which is not yet approved for its primary indication, Alzheimer's.